In a surveillance study of candidemia in cancer patients that was conducted by the European Organization for Research and Treatment of Cancer, 249 episodes were noted; Candida albicans was isolated in 70% (63) of the 90 cases involving patients with solid tumors (tumor patients) and in 36% (58) of the 159 involving those with hematologic disease (hematology patients). Neutropenia in tumor patients and acute leukemia and antifungal prophylaxis in hematology patients were significantly associated with non-albicans candidemia in a multivariate analysis. Overall 30-day mortality was 39% (97 of 249). In a univariate analysis, Candida glabrata was associated with the highest mortality rate (odds ratio, 2.66). Two multivariate analyses showed that mortality was associated with older age and severity of the underlying disease. Among hematology patients, additional factors associated with mortality were allogeneic bone marrow transplantation, septic shock, and lack of antifungal prophylaxis.
In the past decade, the role of fungal organisms as a cause
In 1992 the Invasive Fungal Infection Group of the European Organization for Research and Treatment of Cancer (EORTC) of nosocomial infections in hospitalized patients has increased substantially. Data from American hospitals belonging to the implemented a surveillance study of candidemia in cancer patients at centers participating in the group's activities. In a 2-National Nosocomial Infections Surveillance System showed that the incidence of nosocomial fungal infections increased year period, 270 episodes were noted, of which 249 (92%) were candidemias and 21 (8%) were other fungemias. In the from 2.0 to 3.8 infections/1,000 discharges from 1980 to 1990, with the incidence of nosocomial candidemia increasing from present article we analyze the episodes of candidemia with the aim of (1) establishing a clinical description of candidemia in 1.0 to 4.9 infections/1,000 discharges. Candida albicans accounted for about 60% of the isolated pathogens, followed by cancer patients, (2) understanding factors associated with the emergence of non-albicans species of Candida, and (3) underother Candida species (19%) and other fungi (21%) [1, 2] .
In recent years, an increasing incidence of non-albicans canstanding factors associated with deaths occurring within 30 days following the onset of candidemia. didal infections has been reported, although C. albicans still causes Ç60% of the cases [3, 4] . To the best of our knowledge, no multicenter surveillance study of nosocomial candidemia Materials and Methods has previously been performed in Europe, because of the lack
The surveillance study lasted from 1 November 1992 to 31 of a centralized surveillance system. However, there are several October 1994 and was conducted in 30 tertiary care or univerreports from individual centers that have witnessed a progressity medical centers located in Europe (n Å 28) and in the sive increase in the rates of nosocomial candidemias, both in Middle East (n Å 2). A form was sent to every participating the global population of hospitalized patients [5 -7] and in the investigator on a monthly basis, asking him or her to report subgroup of cancer patients [8, 9] . how many cases of candidemia were seen at each institution during the previous month. For every case of candidemia, the participating investigator was required to fill out a clinical report form on the basis of inpatient or outpatient hospital 1072 Viscoli et al. CID 1999; 28 (May) Definitions and Classifications fever, with or without positive cultures), another complication (e.g., hemorrhage or a secondary nonfungal infection) or an Candidemia was defined by a Candida species -positive culuncontrolled underlying disease was also present. Death was ture of blood from a patient with cancer (e.g., leukemia, considered to be due to another cause when candidemia was lymphoma, multiple myeloma, or solid tumor) who presented cleared at time of death (as indicated by the lack of fever or with fever. Episodes involving afebrile patients were included positive cultures) and there was another likely cause (usually in the analysis only if they were accompanied by hypotension the underlying disease). and other signs of septic shock. Duration of candidemia was defined as the time interval (days) between the first and last
Methods of Analysis
positive blood cultures (yielding the same pathogen). Persistent candidemia was defined as the persistence of positive blood
In light of the existence of major prestudy and poststudy cultures for ú2 days, from the time of the first positive blood differences in clinical status, predisposing factors, and etiology culture. Fever was defined as an axillary temperature of ú37ЊC.
between patients with solid tumors (tumor patients) and patients Since the standard of care was not the same in all centers with hematologic malignancy (hematology patients), we departicipating in the study, we were forced to use a nonstandard cided to analyze the two groups separately. In addition to a definition of catheter-related candidemia. Indeed, quantification descriptive clinical analysis, two multivariate analyses were of the catheter tip culture was performed only occasionally.
performed with the aim of identifying factors associated with Candidemia was considered to be correlated to the intravenous etiology (albicans vs. non-albicans Candida) and outcome in catheter if the catheter was removed and its culture yielded the both groups of patients. same yeast that had been previously isolated in the blood cul-A univariate logistic regression model, modeling the probature, regardless of the colony count. In all other cases the bility of having infection with non-albicans Candida over that correlation of the infection with the catheter was considered with C. albicans [10] , was used to assess the association of all unknown. No guidelines were given about criteria for catheter variables with the frequency of the etiology of candidemia. removal, and the decision was left to the discretion of the The variables that were significant at the 0.10 level were then participating investigator. Similarly, each participating center evaluated in a multivariate logistic regression model. Variables was allowed to use its standard microbiological methods for that did not reach the 0.05 significance level were then removed isolation and identification. These included at least the germone by one from the model, starting with the least significant tube test to differentiate albicans from non-albicans Candida variable. At the end of this backward selection procedure, the strains and a variety of manual or semiautomatic methods for final multivariate logistic regression model was estimated with species identification.
use of all the available information. The odds ratios were comNeutropenia was defined as an absolute neutrophil count puted as the odds for a patient having C. non-albicans candidelower than 1 1 10 9 /L. Severe neutropenia was defined as an mia, divided by the odds for a patient having that due to absolute neutrophil count lower than 0.1 1 10 9 /L. Break-C. albicans. The univariate logistic model was preferred over through candidemia was defined as candidemia in a patient the x 2 test for the sake of homogeneity of the statistical methods receiving either an orally absorbable agent or an intravenous used in the univariate and multivariate models. antifungal agent given for prophylaxis or therapy, regardless
The following variables were analyzed: geographic location of the in vitro susceptibility of the isolated strain. and other); administration of steroids (yes/no); total parenteral Candidemia was considered to be the primary cause of death nutrition administered in the 30 previous days (yes/no); adminof patients who died within 48 hours following a positive blood istration of antibacterial prophylaxis (yes/no); administration culture, when no other cause (including the primary disease, of antifungal prophylaxis (for solid tumors: yes/no, since paother infections, and hemorrhage) was identified. Candidemia tients who received absorbable and nonabsorbable antifungals was considered to be an associated cause of death when, alwere lumped together because of small numbers; for hematologic diseases: none, nonabsorbable drugs, or absorbable though it was still present at time of death (as indicated by / 9c65$$my02 04-06-99 08:10:09 cida UC: CID drugs); breakthrough fungemia (yes/no); catheter correlation and neck tumors and 23 cases (25%) involving patients with other types of tumors. (yes/no; patients with unknown correlation were excluded from the analysis); granulocyte count (cells 1 10 9 /L) at onset (for About half of the cases of candidemia involved patients without an advanced or relapsing/resistant underlying disease solid tumors: £1/ú1; for hematologic diseases: õ0.1, 0.1 -1, ú1); occurrence of neutropenia in the previous 30 days (50% of those with solid tumors and 55% of those with hematologic diseases). A total of 225 of the 249 episodes of candide-(yes/no); body temperature (ЊC) at onset (£37.9, 38 -38.5, ú38.5); presence of shock (yes/no); and presence of organ mia (90%) involved hospitalized patients. For these patients, the median time from hospitalization to onset of infection was involvement (yes/no).
Multivariate models for survival were derived in a similar 14 days among those with solid tumors and 20 days among those with hematologic malignancies. Almost all hematology way. All variables were scanned for their prognostic effect on duration of survival in a univariate Cox proportional hazards patients and 60% of tumor patients had received antineoplastic chemotherapy in the month prior to onset of candidemia. Conregression model [11, 12] . Patients still alive at day 30 were censored at that point. All variables that were significant at the versely, major surgery (excluding placement of intravenous catheters) was much more common among patients with solid 0.10 level in the univariate analysis were selected for inclusion in a multivariate Cox model. A backward selection procedure tumors (41 of 90; 45%) than among those with hematologic diseases (5 of 159; 3%). was then applied with 0.05 as the significance level for staying in the model. The final multivariate model was then estimated
Over the same period of time prior to candidemia, 141 hematology patients (89%) and 36 tumor patients (40%) had an with use of all available information.
The odds ratio and its 95% confidence interval were comepisode of neutropenia, lasting a median of 11 days (range, 1 -66 days). A total of 212 of 249 patients (85%) had received puted for each variable. The variables considered were the same as for the previous analysis, with the addition of the antibacterial drugs either for prophylaxis or for therapy, and 124 of 249 patients (50%) had received absorbable or nonabfollowing: months from diagnosis of the underlying disease to onset of fungemia (õ1, 1-6, 7-12, ú12 [only for hematologic sorbable antifungal drugs. Of these 124 patients, 60 (50%) had received an orally absorbable or intravenous antifungal drug disease]), type of pathogen (C. albicans/C. non-albicans); and number of pathogens involved (single-agent/mixed infection (34, fluconazole; 15, itraconazole; 11, other). The proportion of patients who had received antifungals was much higher or polymicrobial infection). All the analyses were performed with use of Statistical Analysis Software (SAS Institute, Cary, among hematology patients (106 of 159; 67%) than among tumor patients (18 of 90; 20%). NC) [13, 14] .
Results

Clinical Presentations
The proportions of patients who were neutropenic on the A total of 249 episodes of candidemia involving 245 patients were prospectively recorded. A single fungal strain was isolated first day of candidemia (day of the first positive blood culture) were 20% of those with solid tumors (18 of 90) and 69% of in 223 episodes (89%), whereas in 7 episodes (3%), 2 different fungal strains were isolated (polymicrobial infections). The hematology patients (109 of 159). The proportions of those who were severely neutropenic were 12% (11 of 90) and 53% remaining 19 episodes (8%) were due to mixed infections (with a fungus plus a bacterium). The median number of episodes (85 of 159), respectively. In addition, 47% and 35% of hematology patients and 27% and 28% of tumor patients were receiving reported by each center was 5.5 (range, 1 -36) , with 11 centers reporting ú10 episodes each. steroid treatment and total parenteral nutrition, respectively. Unfortunately, we cannot provide information about the duration of steroid therapy and parenteral nutrition before fungemia
Patient's Characteristics and Histories
or about the dosage of steroids. Fever was a very common initial sign of infection, as it was Of 249 candidemias, 90 occurred in patients with solid tumors and 159 in patients with hematologic malignancies. The present in 99% of the episodes. The only two patients who had no fever at presentation had hypotension and signs suggestive median age was 41 years (range, 2 -81 years) among patients with solid tumors and 56 years (range, 1 -90 years) among of septic shock. Twenty-three of 247 patients (9%) presented with low-grade fever (õ38ЊC). In the majority of patients (220 patients with hematologic malignancies. The overall male/female ratio was 132/117. Most patients with hematologic maligof 249; 88%), fever remained the only sign of infection. Clinically or microbiologically/histologically documented organ nancies had acute leukemia (110 of 159; 69%), but there were also patients with lymphoma (30 cases; 19%) , multiple myinvolvement was present in only 24 patients (10%). There were 10 patients with skin embolic lesions; 4 with pneumonia; 3 eloma (14 cases; 9%), and chronic leukemia (5 cases; 3%). Solid tumors were mainly located in the genitourinary tract (26 with peritonitis; 2 each with esophagitis, hepatosplenic disease, and endophthalmitis; and 1 with endocarditis. In 10% of the cases; 29%) and the gastrointestinal tract (26 cases; 29%). There were also 15 cases (17%) involving patients with head cases (25 of 249), candidemia presented with septic shock.
/ 9c65$$my02 04-06-99 08:10:09 cida UC: CID (4) 20 (13) 24 (10) (47%) and was more frequent among hematology patients
Candida tropicalis 6 (7) 22 (14) 28 (11) (73%) than among tumor patients (26%). There was no differCandida parapsilosis 8 (9) 20 (13) 28 (11) ence in the incidence of persistent candidemia according to
Candida krusei 2 (2) 20 (13) 22 (9) the type of Candida involved. Similarly, there were no major
Other non-albicans Candida differences in age, duration of hospitalization before onset of species 7 (8) 19 (12) 26 (10) candidemia, presence of a central venous line, previous use of parenteral nutrition, steroid administration, administration of antibacterial and antifungal agents, presence of neutropenia, On the first day of candidemia, 242 patients (97%) were stage of disease, and prior administration of chemotherapy, fitted with an intravenous line (31 peripheral lines, 168 central as related to the different strains of Candida. However, the catheters, 42 Port-a-caths [Pharmacia, North Ryde, Australia], respective numbers of cases of candidemia due to various speand 1 combination). The intravenous line was removed and cies were too small to allow definitive conclusions. Concomicultured in 130 cases (54%), and a correlation with the catheter tant infections were documented in 26 cases (10%) and were was demonstrated in 40 cases (31%). Although the numbers due to another fungal organism in 7 cases and to a bacterium are small, a statistically significant difference (P Å .002) was in 19 cases. found in the rate of catheter removal among the seven centers Analysis of factors associated with C. albicans or non-albithat reported more than 10 episodes. This rate varied from 12% cans candidemia. In a univariate logistic regression analysis, (2 of 16) in Strasbourg, France, to 81% (13 of 16) in Riyadh, the variables that were significant at the 0.10 level were breakSaudi Arabia.
through candidemia and absolute neutrophil count at onset (for A total of 210 of 249 patients (84%) were receiving broadpatients with solid tumors) and type of disease, antifungal prospectrum antibacterials for prophylaxis or therapy on the day phylaxis, and antibacterial prophylaxis (for those with hematoof the first positive blood culture. A smaller proportion (77 of logic malignancies). The results of the multivariate analyses 249; 31%) was receiving absorbable antifungal drugs. These are reported in table 2. For tumor patients, after the backward episodes were defined as breakthrough candidemias. Of the 77 selection, the only variable retained was absolute neutrophil breakthrough candidemias, 42 developed in patients receiving count at onset, showing a higher risk of non-albicans candideempirical antifungal therapy and 35 in patients receiving sysmia among neutropenic patients. Among patients with hematotemic prophylaxis (33 patients, fluconazole; 21, amphotericin logic malignancies, type of disease and antifungal prophylaxis B [3, lipid formulations]; 12, itraconazole; 6, other antifungals; were retained in the multivariate model, showing the risk of and 5, various combinations). The proportion of patients with non-albicans candidemia to be higher in patients with leukemia breakthrough candidemia was 40% among hematology patients than in those with other malignancies, as well as in patients and 16% among tumor patients (P õ .001).
receiving antifungal prophylaxis, especially with absorbable drugs, than in those receiving no prophylaxis. Table 1 shows the distribution of the various species of Candida identified in the two patient populations. Overall, Out of 249 patients, 97 (39%) died within 30 days from the onset of candidemia. The overall crude mortality rate did not C. albicans accounted for about half of the episodes of candidemia, and Candida glabrata, Candida tropicalis, Candida krudiffer in the two populations of tumor and hematology patients. Death was considered to be directly attributable to candidemia sei, and Candida parapsilosis each caused 10% of the remaining cases. The other 26 episodes (10%) were caused by in 21 (8%) of 249 patients. In 40 additional patients the fungal infection was considered to be an associated cause of death, a miscellaneous group of non-albicans Candida species, including C. guilliermondi (11 cases); C. lusitaniae (4); C. fathe primary one being the underlying disease (29 patients), a concomitant nonfungal infection (8 patients) or a hemorrhage mata, C. lypolitica, and C. kefyr (2 each); and C. inconspicua, C. norvegiensis, C. zeylanoides, and C. stellatoidea (1 each either a primary or a secondary role in about two-thirds of phylaxis, and shock remained in the final model as prognostic factors. This model showed that advanced age, progressive or deaths (61 of 97), with a candidemia-associated mortality rate of 24%.
Etiology Mortality
resistant underlying disease, the absence of previous antifungal prophylaxis, bone marrow transplantation as last treatment, and Analysis of factors associated with mortality. In a univariate logistic regression analysis, the variables that were signifidevelopment of shock were all independently associated with a high risk of death. cant at the 0.10 level were age, stage of disease, antibacterial prophylaxis, and catheter correlation (among patients with solid
Mortality according to Candida species. Figures 1 and 2 present the Kaplan-Meier survival curves according to the type tumors) and geographic location of the center, age, type of disease, time from diagnosis of underlying disease to onset of of pathogen, with both solid tumors and hematologic malignancies grouped together. Figure 1 shows the overall survival curve candidemia, stage of disease, type of chemotherapy, corticosteroid treatment, antifungal prophylaxis, and shock (among those (all deaths), while figure 2 shows the specific survival curve (i.e., only candidemia-associated deaths). The P value of the with hematologic malignancies). The results of the multivariate analyses are reported in table 3. In tumor patients, after the overall log-rank test comparing the survival according to the pathogen is 0.011 for overall survival and 0.008 for specific backward selection, only age and stage of disease were retained in the final model. Younger age and nonadvanced disease were survival. The comparisons remained significant when the models were stratified for those variables that were shown to affect associated with a lower risk of death than older age and advanced disease. Among patients with hematologic malignansurvival and that were not evenly balanced for all the etiologies (type of underlying disease, stage/severity of the underlying cies, age, stage of disease, last chemotherapy, antifungal pro- disease, use and type of antifungal prophylaxis, and age), with Discussion P values of 0.015 for overall survival and 0.025 for specific This is the first multicenter international surveillance study survival. With respect to C. albicans (1-reference) , the adjusted of candidemia in Europe, and, to our knowledge, the largest hazard ratios for overall survival were 2.66 (95% CI, 1.24 -prospective study of cancer patients with candidemia ever re-5.73) for C. glabrata, 1.99 (95% CI, for C. tropiported. This study provides information about the clinical precalis, 0.58 (95% CI, 0.21 -1.58) for C. parapsilosis, 1.67 (95% sentation of candidemia in cancer patients in Europe, as well CI, 0.68 -4.10) for C. krusei, and 0.53 (95% CI, 0. 17 -1.62) as about the emergence of non-albicans Candida strains and for other Candida strains. C. glabrata was therefore associated about candidemia-associated mortality. The study was not dewith a significantly poorer survival rate than that with the other strains.
signed to provide information about the relative incidence of / 9c65$$my02 04-06-99 08:10:09 cida UC: CID candidemia among cancer patients or about the role of fungal In recent years, a shift has occurred in the etiology of candidemia. Although in most studies C. albicans was still the most organisms among all pathogens causing infection in cancer patients or the role of central intravenous catheters in affecting frequent cause of candidemia, there was an increase in the isolation of non-albicans Candida strains, such as C. parathe risk of candidemia and its outcome. In addition, owing to the short period of surveillance (2 years), this study could not psilosis, C. krusei, C. tropicalis, and C. glabrata [3, 4, 15 -22] . In the present study, non-albicans Candida strains acassess changes in etiology or clinical presentation of candidemias over time.
counted for 51% of the cases, but as already reported [21] , this incidence varied significantly according to the underlying For many years candidal infection was commonly considered a rare event, mainly occurring in patients who were dying as disease. C. albicans occurred significantly more frequently among patients with solid tumors than among those with hemaa result of their underlying disease. The present study shows that this is not completely true. Indeed, Ç50% of patients with tologic malignancies (70% vs. 36%; P õ .0001). By contrast, non-albicans strains of Candida were prevalent among patients candidemia had a nonadvanced disease (i.e., neither a relapsing hematologic disease nor a disseminated tumor). In addition, with hematologic disorders. C. krusei and C. glabrata infections accounted for ú25% of the episodes involving patients candidemia developed relatively shortly after the diagnosis of the underlying disease (in õ6 months in half of the patients with hematologic malignancies and only 6% of those involving patients with solid tumors. with solid tumors and about one-third of those with hematologic malignancies).
The multivariate analysis for factors associated with the emergence of non-albicans candidal infections yielded differCandidemia is definitely a nosocomial infection. In our study, only 10% of the episodes occurred outside of the hospient results in the two populations of patients (with solid tumors or hematologic malignancies). In tumor patients the only factor tal. The clinical presentation included fever in the majority of patients, although there were cases with only low-grade fever.
significantly associated with non-albicans candidemia was being neutropenic at the time the infection was diagnosed. In In 10% of the episodes, candidemia presented with septic shock, thus showing that this event is not merely a complication hematology patients, both antifungal prophylaxis (especially with absorbable drugs) and acute leukemia as the underlying of bacterial infections. Finally, in a relatively small proportion of patients (10%), there was some evidence of deep-seated disease were significantly associated with a higher incidence of non-albicans candidemia. infection at diagnosis. However, this proportion might be underestimated, since the study was not designed to provide inforSeveral reports have focused attention on the increasing rate of colonization with and infection due to the natively resistant mation about the incidence of deep-seated candidal infections, including retinitis, in candidemic patients.
Candida species (C. krusei and C. glabrata) in patients receiving fluconazole [23 -25] . However, this phenomenon has not Breakthrough candidemias accounted for 31% of the episodes (ranging from 16% in cases of solid tumors to 40% been confirmed in large prospective studies [26 -29] . In our study, antifungal prophylaxis (not only with fluconazole) was in cases of leukemia), probably because patients with acute leukemia were more often receiving prophylaxis than were associated with an increased risk of non-albicans candidemia in patients with hematologic malignancies. those with solid tumors. This incidence seems to be higher than the one reported by others, probably because of differences Whether the shifting from C. albicans to non-albicans Candida species as the cause of candidemia is an undesirable in the patients' underlying diseases. Indeed, Nguyen and coworkers reported an incidence of 13%, but no information was event is questionable. In our study, the multivariate analysis for survival showed that candidemia due to a non-albicans given about the patients' predisposing conditions [15] . Nucci et al. found that 25% of their fungemic episodes (10 of 43) Candida species or to C. albicans was not a factor associated with a higher mortality rate. Unfortunately, it was impossible were breakthrough candidemias, but only three of their patients had acute leukemia, while the others presumably had to investigate the association between each Candida species and the mortality rate in a multivariate fashion, because of lymphoma [16] . Non-albicans strains of Candida were isolated in 65% of the cases of breakthrough candidemia (50 of 77) an insufficient number of cases. However, a Kaplan-Meier curve examining the role of different species of Candida in and in 45% of those of nonbreakthrough candidemia (78 of 172) (P Å .007). Morever, 67% of the C. tropicalis and 50% the survival rate showed a significantly better survival rate for other Candida species and C. parapsilosis than for of the C. krusei strains were isolated in breakthrough episodes. Many factors may account for the occurrence of breakthrough C. albicans, while C. glabrata, C. tropicalis, and to a lesser extent C. krusei were associated with worse survival rates candidemias, including resistance to the allocated antifungal drug, pharmacokinetic problems, and insufficient dosage. Unthan for C. albicans. This difference remained significant even after adjustment for those variables significantly affecting fortunately, we cannot give more insight on this issue. However, it should be noted that breakthrough candidemias occurred mortality. Indeed, animal and human studies have shown that C. tropicalis is intrinsically more virulent than C. albicans not only in patients receiving triazole drugs but also in patients receiving amphotericin B, including three receiving lipid com- [30, 31] , while C. parapsilosis is usually considered a nonvirulent strain [17, 21] . Conversely, C. glabrata is not usually pounds.
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